Cardiac Papillary Fibroelastoma
Cardiac papillary fibroelastoma is responsible for 11.5% of all primary cardiac tumors. They are nonmalignant endocardial tumors. Although they are benign, they can form embolic complications. A leader in rare cardiovascular disease research, Protheragen focuses on offering full-service drug discovery and development solutions for cardiac papillary fibroelastoma, a rare heart tumor.
Introduction to Cardiac Papillary Fibroelastoma
Papillary fibroelastoma is a benign neoplasm of the endocardium. While papillary fibroelastoma has traditionally been described as the second most frequent primary cardiac tumor, it has now moved to the first place over cardiac myxomas in the evolving modalities of cardiac imaging. Although papillary fibroelastomas are histologically benign, they may have devastating consequences like myocardial infarction, stroke, transient ischemic attack, pulmonary embolism, syncope, and peripheral embolism.
Fig.1 Diagnostic microscopic features of papillary fibroelastoma. (Zoltowska, D. M., et al., 2021)Pathogenesis of Cardiac Papillary Fibroelastoma
The histogenesis of papillary fibroelastoma has yet to be elucidated. Proposals have included neoplasms and hamartomas, organized thrombi, as well as rare infective or post-infective endocardial responses due to radiation, surgery, or hemodynamic trauma. The most popular explanation is that of the microthrombus theory, which postulates the fusion of small thrombi at the coaptating edges of valves with slight endothelial damage. This hypothesis is also supported by the presence of fibrin, hyaluronic acid, and laminated elastic fibers, which are common constituents of thrombus formation.
Fig.2 Distribution of cardiac papillary fibroelastomas on heart valves. (Neupane, G., et al., 2024)Therapeutics Development for Cardiac Papillary Fibroelastoma
Antiplatelet Agents
As an example, Aspirin is part of the antiplatelet drug class. It works by decreasing platelet aggregation, which minimizes blood clot development.
Anticoagulants
An example of this category would be Warfarin. It acts by disrupting the coagulation cascade, and therefore, blood clots cannot form.
Our Services
Protheragen's capabilities comprise diagnostics and therapeutics as well as the creation of stable disease models and the provision of preclinical study services to accelerate the research and therapy of cardiac papillary fibroelastoma. We also provide essential preclinical pharmacokinetic profiles and safety study capabilities. Integrating these essential services, we provide a streamlined pathway from concept to possible use, customized for the rare cardiovascular disorders.
Therapeutic Development Services
Diverse Platforms
Animal Model Development for Cardiac Papillary Fibroelastoma
Experimental animal models can assist in the identification and validation of biomarkers for early diagnosis, prognostication, and therapeutic monitoring, thereby facilitating optimal management tailored to individual needs. Needing innovative tools in the area of rare cardiovascular diseases, our company offers the development services of animal models that closely replicate the pathophysiological features of papillary fibroelastoma.
For cardiac papillary fibroelastoma, xenograft models mainly involve the implantation of human tumor cells or tissues into immunodeficient animal hosts, most often mice.
Pharmacokinetics and Drug Safety Research Services
Protheragen's scientific achievements and professional services make it a committed partner in rare cardiovascular diseases. We focus on the advanced research and development of cardiac papillary fibroelastoma because we wish to offer tools and expertise that facilitate research for scientific and pharmaceutical discoveries. Feel free to contact us if you have any questions regarding our offered services.
References
- Neupane, Gagan et al. "Cardiac Papillary Fibroelastoma and Cerebrovascular Events: A Systematic Review." CJC open 6.11 (2024): 1259-1273.
- Zoltowska, Dominika M et al. "Cardiac papillary fibroelastoma." Journal of geriatric cardiology: JGC 18.5 (2021): 346-351.
For research use only, not for clinical use.